These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34778985)

  • 21. Lenalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of a non-interventional study and comparison with the pivotal phase 3 clinical trials.
    Knauf W; Aldaoud A; Losem C; Mittermueller J; Neise M; Niemeier B; Harde J; Trarbach T; Potthoff K
    Leuk Res; 2018 May; 68():90-97. PubMed ID: 29579627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Addition of Cyclophosphamide "On Demand" to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma-A Retrospective Review of a Single-center Experience.
    Alahmadi M; Masih-Khan E; Atenafu EG; Chen C; Kukreti V; Tiedemann R; Trudel S; Reece DE
    Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):e195-e203. PubMed ID: 30723035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma.
    Laubach JP; Tuchman SA; Rosenblatt JM; Mitsiades CS; Colson K; Masone K; Warren D; Redd RA; Grayson D; Richardson PG
    Blood Cancer J; 2021 Feb; 11(2):20. PubMed ID: 33563894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic impact of resistance to bortezomib and/or lenalidomide in carfilzomib-based therapies for relapsed/refractory multiple myeloma: The Kyoto Clinical Hematology Study Group, multicenter, pilot, prospective, observational study in Asian patients.
    Kawaji-Kanayama Y; Kobayashi T; Muramatsu A; Uchiyama H; Sasaki N; Uoshima N; Nakao M; Takahashi R; Shimura K; Kaneko H; Kiyota M; Wada K; Chinen Y; Hirakawa K; Fuchida SI; Shimazaki C; Matsumura-Kimoto Y; Mizutani S; Tsukamoto T; Shimura Y; Horiike S; Taniwaki M; Kuroda J;
    Cancer Rep (Hoboken); 2022 Feb; 5(2):e1476. PubMed ID: 34124862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.
    Besson L; Charrier E; Karlin L; Allatif O; Marçais A; Rouzaire P; Belmont L; Attal M; Lombard C; Salles G; Walzer T; Viel S
    Front Immunol; 2018; 9():704. PubMed ID: 29706958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A Newly Diagnosed Case of Multiple Myeloma in Which Lenalidomide Was Continued after Surgery for a Pancreatic Neuroendocrine Tumor That Developed during Lenalidomide Maintenance Therapy].
    Kuroda H; Yoshida M; Usami M; Shimoyama S; Sakamoto H; Yamada M; Fujii S; Maeda M; Fujita M; Kanari Y; Sato T; Kato J
    Gan To Kagaku Ryoho; 2015 Aug; 42(8):1009-12. PubMed ID: 26321720
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial.
    Goldschmidt H; Mai EK; Dürig J; Scheid C; Weisel KC; Kunz C; Bertsch U; Hielscher T; Merz M; Munder M; Lindemann HW; Hügle-Dörr B; Tichy D; Giesen N; Hose D; Seckinger A; Huhn S; Luntz S; Jauch A; Elmaagacli A; Rabold B; Fuhrmann S; Brossart P; Goerner M; Bernhard H; Hoffmann M; Hillengass J; Raab MS; Blau IW; Hänel M; Salwender HJ;
    Leukemia; 2020 Jul; 34(7):1853-1865. PubMed ID: 32034285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
    Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
    Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
    Fouquet G; Tardy S; Demarquette H; Bonnet S; Gay J; Debarri H; Herbaux C; Guidez S; Michel J; Perrot A; Serrier C; Miljkovic D; Avet Loiseau H; Facon T; Hulin C; Leleu X
    Cancer; 2013 Oct; 119(20):3680-6. PubMed ID: 23921945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delayed-onset cutaneous eruption associated with lenalidomide in setting of multiple myeloma.
    Buonomo M; Kabbur G; El Jurdi N; Giubellino A; Schultz B
    Dermatol Online J; 2021 Dec; 27(12):. PubMed ID: 35499443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low-dose lenalidomide and dexamethasone therapy after melphalan-prednisolone induction in elderly patients with newly diagnosed multiple myeloma.
    Onishi Y; Yokoyama H; Katsuoka Y; Ito T; Kimura T; Yamamoto J; Nakajima S; Sasaki O; Ara T; Minauchi K; Fukuhara O; Kobayashi N; Noji H; Ota S; Harigae H
    Ann Hematol; 2020 Oct; 99(10):2351-2356. PubMed ID: 32865607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
    Gay F; Vincent Rajkumar S; Falco P; Kumar S; Dispenzieri A; Petrucci MT; Gertz MA; Boccadoro M; Keith Stewart A; Palumbo A
    Eur J Haematol; 2010 Sep; 85(3):200-8. PubMed ID: 20477865
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
    Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of coagulation by lenalidomide-based regimens for the treatment of multiple myeloma.
    Isozumi Y; Arai R; Fujimoto K; Koyama T
    PLoS One; 2013; 8(5):e64369. PubMed ID: 23696885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.
    Baertsch MA; Mai EK; Hielscher T; Bertsch U; Salwender HJ; Munder M; Fuhrmann S; Dührsen U; Brossart P; Neben K; Schlenzka J; Kunz C; Raab MS; Hillengaß J; Jauch A; Seckinger A; Hose D; Luntz S; Sonneveld P; Lokhorst H; Martin H; Goerner M; Hoffmann M; Lindemann HW; Bernhard H; Blau IW; Scheid C; Besemer B; Weisel KC; Hänel M; Dürig J; Goldschmidt H;
    Blood Cancer J; 2021 Jan; 11(1):1. PubMed ID: 33414374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era.
    Okura M; Ida N; Yamauchi T
    Med Oncol; 2020 Oct; 37(11):103. PubMed ID: 33068194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation.
    Chakraborty R; Muchtar E; Kumar SK; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Warsame R; Kourelis T; Gonsalves W; Gertz MA
    Leukemia; 2018 Mar; 32(3):712-718. PubMed ID: 28848227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lenalidomide alone or lenalidomide plus dexamethasone significantly inhibit IgG and IgM in vitro... A possible explanation for their mechanism of action in treating multiple myeloma.
    Shannon E; Sandoval F; Greig N; Stagg P
    Int Immunopharmacol; 2012 Feb; 12(2):441-6. PubMed ID: 22245427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.